{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:12:39Z","timestamp":1791277959698,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U10 CA180886"],"award-info":[{"award-number":["U10 CA180886"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U24 CA114766"],"award-info":[{"award-number":["U24 CA114766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U24 CA196173"],"award-info":[{"award-number":["U24 CA196173"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U10 CA98543"],"award-info":[{"award-number":["U10 CA98543"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U10 CA98413"],"award-info":[{"award-number":["U10 CA98413"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U10 CA180899"],"award-info":[{"award-number":["U10 CA180899"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick&apos;s Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA197695"],"award-info":[{"award-number":["R35 CA197695"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current strategies to treat pediatric acute lymphoblastic leukemia rely on risk stratification algorithms using categorical data. We investigated whether using continuous variables assigned different weights would improve risk stratification. We developed and validated a multivariable Cox model for relapse-free survival (RFS) using information from 21199 patients. We constructed risk groups by identifying cutoffs of the COG Prognostic Index (PI<jats:sub>COG<\/jats:sub>) that maximized discrimination of the predictive model. Patients with higher PI<jats:sub>COG<\/jats:sub> have higher predicted relapse risk. The PI<jats:sub>COG<\/jats:sub> reliably discriminates patients with low vs. high relapse risk. For those with moderate relapse risk using current COG risk classification, the PI<jats:sub>COG<\/jats:sub> identifies subgroups with varying 5-year RFS. Among current COG standard-risk average patients, PI<jats:sub>COG<\/jats:sub> identifies low and intermediate risk groups with 96% and 90% RFS, respectively. Similarly, amongst current COG high-risk patients, PI<jats:sub>COG<\/jats:sub> identifies four groups ranging from 96% to 66% RFS, providing additional discrimination for future treatment stratification. When coupled with traditional algorithms, the novel PI<jats:sub>COG<\/jats:sub> can more accurately risk stratify patients, identifying groups with better outcomes who may benefit from less intensive therapy, and those who have high relapse risk needing innovative approaches for cure.<\/jats:p>","DOI":"10.1038\/s41375-024-02166-1","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T12:02:58Z","timestamp":1707998578000},"page":"720-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children\u2019s Oncology Group Report"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-9839","authenticated-orcid":false,"given":"N. J.","family":"DelRocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-4700","authenticated-orcid":false,"given":"M. L.","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Borowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-8195","authenticated-orcid":false,"given":"K. R.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zweidler-McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. W.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8409-0589","authenticated-orcid":false,"given":"L. A.","family":"Mattano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-2168","authenticated-orcid":false,"given":"R. J.","family":"Schore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6626-2773","authenticated-orcid":false,"given":"M. J.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. L.","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. L.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9844-730X","authenticated-orcid":false,"given":"A. J.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. A.","family":"Heerema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. C.","family":"Reshmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Gastier-Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-4043","authenticated-orcid":false,"given":"K. G.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-1850","authenticated-orcid":false,"given":"C. G.","family":"Mullighan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Willman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-3870","authenticated-orcid":false,"given":"N.","family":"Winick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-4167","authenticated-orcid":false,"given":"W. L.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"D. T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8547-1658","authenticated-orcid":false,"given":"E. A.","family":"Raetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-3478","authenticated-orcid":false,"given":"M.","family":"Devidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Kairalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2166_CR1","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938\u201348. https:\/\/doi.org\/10.1200\/JCO.2014.59.1636.","journal-title":"J Clin Oncol"},{"key":"2166_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/nejmra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N. Engl J Med. 2015;373:1541\u201352. https:\/\/doi.org\/10.1056\/nejmra1400972.","journal-title":"N. Engl J Med"},{"key":"2166_CR3","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/cncr.31099","volume":"124","author":"WL Salzer","year":"2018","unstructured":"Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, et al. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children\u2019s Oncology Group study AALL1131. Cancer. 2018;124:1150\u20139. https:\/\/doi.org\/10.1002\/cncr.31099.","journal-title":"Cancer"},{"key":"2166_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","volume":"36","author":"D O\u2019Connor","year":"2018","unstructured":"O\u2019Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R, et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36:34\u201343. https:\/\/doi.org\/10.1200\/JCO.2017.74.0449.","journal-title":"J Clin Oncol"},{"key":"2166_CR5","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1182\/BLOOD.2019003191","volume":"135","author":"A Enshaei","year":"2020","unstructured":"Enshaei A, O\u2019Connor D, Bartram J, Hancock J, Harrison CJ, Hough R, et al. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood. 2020;135:1438\u201346. https:\/\/doi.org\/10.1182\/BLOOD.2019003191.","journal-title":"Blood"},{"key":"2166_CR6","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","volume":"111","author":"MJ Borowitz","year":"2008","unstructured":"Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study. Blood. 2008;111:5477\u201385. https:\/\/doi.org\/10.1182\/blood-2008-01-132837.","journal-title":"Blood"},{"key":"2166_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016:580\u20138. https:\/\/doi.org\/10.1182\/asheducation-2016.1.580.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2166_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.19.01086","volume":"38","author":"KW Maloney","year":"2020","unstructured":"Maloney KW, Devidas M, Wang C, Mattano LA, Friedmann AM, Buckley P, et al. Outcome in children with standard-risk b-cell acute lymphoblastic leukemia: Results of children\u2019s oncology group trial aall0331. J Clin Oncol. 2020;38:602\u201312. https:\/\/doi.org\/10.1200\/JCO.19.01086.","journal-title":"J Clin Oncol"},{"key":"2166_CR9","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","volume":"34","author":"EC Larsen","year":"2016","unstructured":"Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children\u2019s oncology group study AALL0232. J Clin Oncol. 2016;34:2380\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.62.4544.","journal-title":"J Clin Oncol"},{"key":"2166_CR10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.20.00494","volume":"39","author":"AL Angiolillo","year":"2021","unstructured":"Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from Children\u2019s Oncology Group AALL0932. J Clin Oncol. 2021;39:1437\u201347. https:\/\/doi.org\/10.1200\/JCO.20.00494.","journal-title":"J Clin Oncol"},{"key":"2166_CR11","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3324\/haematol.2018.204545","volume":"104","author":"MJ Burke","year":"2019","unstructured":"Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, et al. Replacing cyclophosphamide\/cytarabine\/ mercaptopurine with cyclophosphamide\/ etoposide during consolidation\/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: A report from the COG. Haematologica. 2019;104:986\u201392. https:\/\/doi.org\/10.3324\/haematol.2018.204545.","journal-title":"Haematologica"},{"key":"2166_CR12","doi-asserted-by":"crossref","unstructured":"Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. 2nd ed. Springer Nature Switzerland, Cham, 2019.","DOI":"10.1007\/978-3-030-16399-0"},{"key":"2166_CR13","doi-asserted-by":"crossref","unstructured":"Harrell FE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. 2nd ed. Springer Nature Switzerland, Cham, 2015.","DOI":"10.1007\/978-3-319-19425-7"},{"key":"2166_CR14","doi-asserted-by":"publisher","unstructured":"Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13. https:\/\/doi.org\/10.1186\/1471-2288-13-33.","DOI":"10.1186\/1471-2288-13-33"},{"key":"2166_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7326\/M22-0844","volume":"176","author":"DJ McLernon","year":"2023","unstructured":"McLernon DJ, Giardiello D, Van Calster B, Wynants L, van Geloven N, van Smeden M, et al. Assessing performance and clinical usefulness in prediction models with survival outcomes: practical guidance for Cox proportional hazards models. Ann Intern Med. 2023;176:105\u201314. https:\/\/doi.org\/10.7326\/M22-0844.","journal-title":"Ann Intern Med"},{"key":"2166_CR16","unstructured":"Harrell Jr FE. rms: Regression Modeling Strategies. R package version 6.3-0, <https:\/\/CRAN.R-project.org\/package=rms> (2022)."},{"key":"2166_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1214\/08-AOAS169","volume":"2","author":"H Ishwaran","year":"2008","unstructured":"Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann Appl Stat 2008;2:841\u201360.","journal-title":"Ann Appl Stat"},{"key":"2166_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.32614\/rj-2018-005","volume":"10","author":"CJK Fouodo","year":"2018","unstructured":"Fouodo CJK, K\u00f6nig IR, Weihs C, Ziegler A, Wright MN. Support vector machines for survival analysis with R. R J. 2018;10:412\u201323. https:\/\/doi.org\/10.32614\/rj-2018-005.","journal-title":"R J"},{"key":"2166_CR19","first-page":"477","volume":"22","author":"P Buehlmann","year":"2007","unstructured":"Buehlmann P, Hothorn T. Boosting algorithms: regularization, prediction and model fitting (with discussion). Stat Sci. 2007;22:477\u2013505.","journal-title":"Stat Sci"},{"key":"2166_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2436\/20.8080.02.51","volume":"41","author":"I Barrio","year":"2017","unstructured":"Barrio I, Rodr\u00edguez-Alvarez MX, Meira-Machado L, Esteban C, Arostegui I. Comparison of two discrimination indexes in the categorisation of continuous predictors in time-to-event studies. Sort 2017;41:73\u201392. https:\/\/doi.org\/10.2436\/20.8080.02.51.","journal-title":"Sort"},{"key":"2166_CR21","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/ (2022)."},{"key":"2166_CR22","doi-asserted-by":"crossref","unstructured":"Chen Y, Millar JA. Machine learning techniques in cancer prognostic modeling and performance assessment. In: Frontiers of biostatistical methods and applications in clinical oncology. Springer Nature Singapore, Singapore 189721, 2017; 179\u2013230.","DOI":"10.1007\/978-981-10-0126-0_13"},{"key":"2166_CR23","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2016.71.4774","volume":"35","author":"N Winick","year":"2017","unstructured":"Winick N, Devidas M, Chen S, Maloney K, Larsen E, Mattano L, et al. Impact of initial CSF findings on outcome among patients with national cancer institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2017;35:2527\u201334. https:\/\/doi.org\/10.1200\/JCO.2016.71.4774.","journal-title":"J Clin Oncol"},{"key":"2166_CR24","doi-asserted-by":"publisher","first-page":"e828","DOI":"10.1016\/S2352-3026(21)00304-5","volume":"8","author":"A Enshaei","year":"2021","unstructured":"Enshaei A, Vora A, Harrison CJ, Moppett J, Moorman AV. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97\/99 and UKALL2003 clinical trials. Lancet Haematol. 2021;8:e828\u2013e839. https:\/\/doi.org\/10.1016\/S2352-3026(21)00304-5.","journal-title":"Lancet Haematol"},{"key":"2166_CR25","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1182\/blood-2007-10-117150","volume":"111","author":"R Mody","year":"2008","unstructured":"Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111:5515\u201323. https:\/\/doi.org\/10.1182\/blood-2007-10-117150.","journal-title":"Blood"},{"key":"2166_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2352-3026(19)30050-X","volume":"6","author":"DA Mulrooney","year":"2019","unstructured":"Mulrooney DA, Hyun G, Ness KK, Bhakta N, Pui CH, Ehrhardt MJ, et al. The changing burden of late health outcomes in adult survivors of childhood acute lymphoblastic leukemia: a report from the St. Jude Lifetime cohort study. Lancet Haematol. 2019;6:306\u201316. https:\/\/doi.org\/10.1016\/S2352-3026(19)30050-X.","journal-title":"Lancet Haematol"},{"key":"2166_CR27","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1200\/JCO.20.00493","volume":"38","author":"SB Dixon","year":"2020","unstructured":"Dixon SB, Chen Y, Yasui Y, Pui CH, Hunger SP, Silverman LB, et al. Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. J Clin Oncol. 2020;38:3418\u201329. https:\/\/doi.org\/10.1200\/JCO.20.00493.","journal-title":"J Clin Oncol"},{"key":"2166_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41512-019-0060-y","volume":"3","author":"LE Cowley","year":"2019","unstructured":"Cowley LE, Farewell DM, Maguire S, Kemp AM. Methodological standards for the development and evaluation of clinical prediction rules: a review of the literature. Diagn. Progn Res. 2019;3:1\u201323. https:\/\/doi.org\/10.1186\/s41512-019-0060-y.","journal-title":"Diagn. Progn Res"},{"key":"2166_CR29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","volume":"131","author":"B Wood","year":"2018","unstructured":"Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018;131:1350\u20139. https:\/\/doi.org\/10.1182\/blood-2017-09-806521.","journal-title":"Blood"},{"key":"2166_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54:1376\u201389. https:\/\/doi.org\/10.1038\/s41588-022-01159-z.","journal-title":"Nat Genet"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02166-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02166-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02166-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T15:03:19Z","timestamp":1712329399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02166-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2166"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02166-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJB has been on an advisory board and received honoraria from Amgen and received honoraria from Blueprint Medicines; JAK owns common stock in Johnson & Johnson. PZM employment at ImmunoGen. BW has served as a consultant for Amgen and has received research funding from Celgene\/Juno, Kite, Novartis, Wugen, Macrogenics, Biosight, and Beam; EAR has received institutional research funding from Pfizer and serves on a DSMB for Celgene\/BMS; SPH owns common stock in Amgen and has received honoraria from Amgen, Jazz, and Servier. WLC serves as a consultant for Merck. LAM has received consulting fees from Novartis and Pfizer, and owns stock in Pfizer. CGM serves on an advisory board for Illumina; has received research funding from Pfizer, AbbVie; and receives royalties from Cyrus.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}